National Bank of Greece (NYSE: NBG) 27% LOWER; Greek Council of Systemic Stability imposed capital controls from today until July 6th after Greece and its creditors failed to revolve the debt crisis and Greek Prime …
StreetInsider · 16 hours ago
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the August 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRPT options …
NASDAQ · 6/25/2015
Sarepta Therapeutics
This shows that insiders were bullish on the stock. Medical research and drug development company, Sarepta Therapeutics Inc (NASDAQ:SRPT) lost around 8% of its value so far today. The stock had gained in triple digits …
INSIDER MONKEY · 11 hours ago
hedge funds
In-depth coverage >
More from Bing News
What: Shares of Sarepta Therapeutics (NASDAQ:SRPT), a clinical-stage biopharmaceutical company ... Clearly this is worrying existing shareholders. Now what: Sarepta stock could very well be the poster child for overreactions and emotional trading (hint ...
The Motley Fool · BySean Williams · 10 hours ago
Sarepta Therapeutics
marking the third consecutive day the stock has increased. Some of the biggest losers among healthcare stocks include: Sarepta Therapeutics Inc (SRPT): SRPT stock is down 8.2% today. The Spectranetics Corp (SPNC): SPNC stock is down 5.4% today.
Investor Place · 11 hours ago
Healthcare Stocks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) seems to be taking this especially hard despite ... Shares of Sarepta were down nearly 10% at $28.29 on Monday afternoon. The stock has a consensus analyst price …
24/7 Wall ST · 10 hours ago
The company traded at $10.50 + 0.80 (8.25 percent) on 142,847 total stock volume. Sarepta Therapeutics Inc. (SRPT) has posted a new high of 32.94 above a previous 52-week high of 32.66. The company traded at $32.
Fx Pips · 6/24/2015
total stock
Earlier this year, we followed Perceptive Advisors, a multi-billion dollar biotech specialist hedge fund, into Sarepta Therapeutics (SRPT). That stock is up 155% since early February. Given the value of following the …
Forbes · 6/24/2015
Billionaire Investors
historical control." However, Yee added that the Ebola trial was always a "free upside opportunity" because the real value of the stock resides in the company's hepatitis B program which was acquired earlier this year …
Smallcap Network · ByJohn Udovich · 6/22/2015
TKM Ebola
Sarepta Therapeutics (NASDAQ:SRPT) has earned a consensus recommendation of “Buy” from the twenty brokerages that are covering the company, Market Beat Ratings reports. One equities research analyst has rated the stock with a sell … · 6/25/2015